Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
10-day decitabine versus 3+7 induction chemotherapy followed by allografting in older patients with acute myeloid leukemia
2014-001486-27Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine, daunorubicin, cytarabine, idarubicin and etoposide in acute myeloid leukemia (AML) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Oct 2014; status: completed.
02
Drugs
decitabinedaunorubicincytarabineidarubicinetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2014-001486-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001486-27.